Cargando…
IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer
Breast cancer bone metastasis is currently incurable, ~75% of patients with late-stage breast cancer develop disease recurrence in bone and available treatments are only palliative. We have previously shown that production of the pro-inflammatory cytokine interleukin-1B (IL-1B) by breast cancer cell...
Autores principales: | Tulotta, Claudia, Lefley, Diane V., Moore, Charlotte K., Amariutei, Ana E., Spicer-Hadlington, Amy R., Quayle, Lewis A., Hughes, Russell O., Ahmed, Khawla, Cookson, Victoria, Evans, Catherine A., Vadakekolathu, Jayakumar, Heath, Paul, Francis, Sheila, Pinteaux, Emmanuel, Pockley, A. Graham, Ottewell, Penelope D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295314/ https://www.ncbi.nlm.nih.gov/pubmed/34290237 http://dx.doi.org/10.1038/s41523-021-00305-w |
Ejemplares similares
-
The role of IL-1B in breast cancer bone metastasis
por: Tulotta, Claudia, et al.
Publicado: (2018) -
Novel Methods of Targeting IL-1 Signalling for the Treatment of Breast Cancer Bone Metastasis
por: Zhou, Jiabao, et al.
Publicado: (2022) -
Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts
por: Lefley, Diane, et al.
Publicado: (2019) -
IL-1 drives breast cancer growth and bone metastasis in vivo
por: Holen, Ingunn, et al.
Publicado: (2016) -
Transcriptomic Profiling Reveals Novel Candidate Genes and Signalling Programs in Breast Cancer Quiescence and Dormancy †
por: Quayle, Lewis A., et al.
Publicado: (2021)